新辅助化疗-免疫治疗后组织病理学特征与临床结局的关联:随机双盲安慰剂对照III期IMagyn050/GOG3015/ENGOT-ov39研究的亚组分析
该研究对III期IMagyn050研究中243例接受新辅助化疗/贝伐珠单抗联合阿替利珠单抗或安慰剂后行间歇性肿瘤细胞减灭术的患者组织进行中心病理评分。结果显示两治疗组间无进展生存期(16.9个月 vs 19.2个月,p=0.21)和总生存期(41.5个月 vs 45.1个月,p=0.67)无显著差异;残留肿瘤3+与进展风险增加相关(HR 2.0,p<0.01),广泛炎症与死亡风险降低相关(HR 0.65,p=0.02)。
要点
- 两治疗组间PFS和OS无显著差异,残留肿瘤3+与进展风险增加相关(HR 2.0)。
- 广泛炎症与死亡风险降低相关(HR 0.65,p=0.02),并可能预测免疫治疗反应(OR 2.9)。
- 组织病理学特征在治疗组间及组织部位间无显著差异。
核心结论
- 间歇性肿瘤细胞减灭术标本的详细组织学评估可识别炎症和残留肿瘤等特征,可能为某些临床结局提供线索。
- 未来工作可能利用新兴工具进一步洞察结局。
研究设计与样本
- 随机双盲安慰剂对照III期IMagyn050/GOG3015/ENGOT-ov39研究的亚组分析。
- 预设解剖部位的可评估组织来自新辅助化疗/贝伐珠单抗联合阿替利珠单抗或安慰剂后行间歇性肿瘤细胞减灭术的患者,共243例可评估的新辅助化疗患者。
- 进行中心组织病理学评分并与临床结局进行分析。
主要发现
- 预设人群中48.1%肿瘤为PD-L1阳性。
- 两治疗组间PFS无显著差异(16.9个月 vs 19.2个月,p=0.21)。
- 两治疗组间OS无显著差异(41.5个月 vs 45.1个月,p=0.67)。
- 大量残留肿瘤(3+)在阿替利珠单抗组为26%,安慰剂组为24%(p=0.94)。
- 多数显示无(1+)坏死(阿替利珠单抗组82% vs 安慰剂组96%,p=0.69),中度(2+)至重度(3+)纤维化(71% vs 75%,p=0.82),广泛(2+)炎症(53% vs 47%,p=0.48)。
局限性
- 未来工作可能利用新兴工具进一步洞察结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Histopathologic characteristics after neoadjuvant chemotherapy (NACT) may correlate with outcome. This study evaluates histopathologic features after immunotherapy and NACT/bevacizumab, and associated clinical outcomes. METHODS: Evaluable tissue from IMagyn050/GOG3015/ENGOT-ov39 patients from prespecified anatomic sites from interval cytoreductive surgery (ICS) after NACT/bevacizumab plus atezolizumab/placebo underwent central histopathologic scoring and analyzed with clinical outcomes. RESULTS: The predefined population had 243 evaluable NACT patients, with 48.1% tumors being PD-L1-positive. No statistically significant differences in PFS (16.9 months vs. 19.2 months, p = 0.21) or OS (41.5 months vs. 45.1 months, p = 0.67) between treatment arms were seen. Substantial residual tumor (RT) (3+) was identified in 26% atezolizumab vs. 24% placebo arms (p = 0.94). Most showed no (1+) necrosis (82% vs. 96%, respectively, p = 0.69), moderate (2+) to severe (3+) fibrosis (71% vs. 75%, respectively, p = 0.82), and extensive (2+) inflammation (53% vs. 47% respectively, p = 0.48). No significant histopathologic differences were identified by tissue site or by arm. Multivariate analyses showed increased risk for progression with moderate and substantial RT (13.6 mon vs. 21.1 mon, hazard ratio 2.0, p < 0.01; 13.6 mon vs. 21.1 mon, HR 1.9, p < 0.01, respectively); but decreased risk for death with extensive inflammation (46.9 mon vs. 36.3 mon, HR 0.65, p = 0.02). Inflammation also correlated with greater likelihood of response to NACT/bevacizumab plus immunotherapy (odds ratio 2.9, p < 0.01). Modeling showed inflammation as a consistent but modest predictor for OS. CONCLUSIONS: Detailed histologic assessment of ICS specimens appear to identify characteristics, such as inflammation and residual tumor, that may provide insight to certain clinical outcomes. Future work potentially leveraging emerging tools may provide further insight into outcomes.
引用
- Mhawech-Fauceglia P, McCarthy D, Tonooka A, et al. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024. PMID: 38554625. doi:10.1016/j.ygyno.2024.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。